Seelos Therapeutics – Consensus Indicates Potential 352.0% Upside

Broker Ratings
[shareaholic app="share_buttons" id_name="post_below_content"]

Seelos Therapeutics found using ticker (SEEL) have now 2 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The range between the high target price and low target price is between 12 and 4 with a mean TP of 8. With the stocks previous close at 1.77 this now indicates there is a potential upside of 352.0%. The 50 day MA is 1.02 and the 200 day moving average is 0.98. The company has a market cap of $96m. Company Website: http://seelostherapeutics.com

The potential market cap would be $432m based on the market concensus.

Seelos Therapeutics, a clinical-stage biopharmaceutical company, focuses on developing and commercializing of novel technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company’s lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorder and post-traumatic stress disorder; SLS-005, a protein stabilizer for the treatment of Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson’s disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics was founded in 2016 and is headquartered in New York, New York.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:

      Search

      Search